To amend the Federal Food, Drug, and Cosmetic Act to encourage the development of vaccines to prevent, treat, or mitigate opioid, cocaine, methamphetamine, or alcohol use disorder, to establish an x-prize for the development of such a vaccine, and for other purposes.
H.R. 7827 aims to accelerate the development of vaccines to prevent or treat addiction to opioids, cocaine, methamphetamine, and alcohol by amending federal drug approval laws. The bill automatically designates any such vaccine as a "breakthrough therapy" and "fast track product," allowing the FDA to review and approve these vaccines more quickly than standard drugs. Additionally, the legislation creates a one-time "Vaccine X-Prize" worth $1 billion that would be awarded to the first company to develop, obtain FDA approval for, and mass-produce an eligible vaccine for one of these substance use disorders. All these expedited review provisions and the prize program are set to expire after ten years. The bill targets pharmaceutical companies and researchers working on addiction treatments, with potential taxpayer funding required only if a vaccine actually meets the prize criteria.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.